Accuray Drives Growth in Radiosurgery for Early-Stage Prostate Cancer

Tue, 08/30/2011 - 7:41am

SUNNYVALE, Calif., Aug. 30, 2011 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today a significant increase in use of the CyberKnife® Robotic Radiosurgery System for prostate SBRT (stereotactic body radiotherapy). In Q4 2011, the company experienced a 24 percent increase in worldwide prostate treatments over Q4 2010 and a 17 percent increase over Q3 2011. Continued momentum in the adoption of CyberKnife prostate SBRT as supported by a growing body of clinical evidence, as well as greater patient awareness and demand for innovative treatment options, has helped Accuray achieve this notable increase in use of CyberKnife prostate SBRT.

Earlier in the year, Accuray announced the first publication from the expanding foundation of maturing prostate SBRT long term studies documenting five-year outcomes of prostate cancer patients treated with the CyberKnife System ("Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: Five-Year Outcomes," Radiation Oncology, January 10, 2011). The multi-center study, which combines data from patients at Stanford University in Stanford, Calif. and Naples Community Hospital in Naples, Fla., found that 93 percent of patients had no recurrence of their cancer at a median follow-up of five years, a rate that compares favorably to results obtained with other treatment modalities, including surgery and conventional radiation therapy. The study also found generally low levels of urinary and rectal toxicity, concluding that CyberKnife SBRT can achieve high rates of disease control while sparing critical structures, thereby minimizing undesirable side effects typically associated with other prostate cancer treatments and preserving patients' qua





Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.